Literature DB >> 15956368

Flow cytometry susceptibility testing for the antifungal caspofungin.

M Mitchell1, M Hudspeth, A Wright.   

Abstract

Rapid antifungal susceptibility testing for the antifungal agent caspofungin can be performed using flow cytometry (FC). An FC procedure using acridine orange provided minimum inhibitory concentration (MIC) results within 7 to 9 h which were compared with results obtained using the NCCLS M27-A2 protocol. To evaluate the consistency of this method, susceptibility testing using caspofungin was performed using 73 isolates of eight different species of Candida from various clinical samples in Central California. Macrotiter or microdilution tests were performed according to the NCCLS M27-A2 protocol, and the MICs were compared to those provided by our flow cytometry method. All isolates tested had results within the sensitive interpretive category, and 90% of the results compared within 1 dilution, showing excellent agreement between the methods. The MIC at which 50% of the isolates tested were inhibited (MIC50) and the MIC90 of caspofungin for all eight Candida species were within 1 dilution. This flow cytometer 7-h protocol for testing the antifungal susceptibility of Candida species to caspofungin provided results equivalent to those obtained with the M27-A2 protocol.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15956368      PMCID: PMC1151939          DOI: 10.1128/JCM.43.6.2586-2589.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  12 in total

1.  Caspofungin activity against clinical isolates of fluconazole-resistant Candida.

Authors:  Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

2.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

3.  Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test.

Authors:  R Ramani; V Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

Review 4.  Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors:  T C White; K A Marr; R A Bowden
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

5.  In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance.

Authors:  Stefano P Bachmann; Thomas F Patterson; José L López-Ribot
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

6.  Rapid susceptibility testing of fungi by flow cytometry using vital staining.

Authors:  C Wenisch; K F Linnau; B Parschalk; K Zedtwitz-Liebenstein; A Georgopoulos
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

7.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

8.  In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

Authors:  M A Pfaller; D J Diekema; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

9.  Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.

Authors:  M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

10.  Amphotericin B susceptibility testing of Candida species by flow cytometry.

Authors:  M R O'Gorman; R L Hopfer
Journal:  Cytometry       Date:  1991
View more
  4 in total

Review 1.  Antifungal Susceptibility Testing: Current Approaches.

Authors:  Elizabeth L Berkow; Shawn R Lockhart; Luis Ostrosky-Zeichner
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

2.  Comparison of the Etest and a rapid flow cytometry-based method with the reference CLSI broth microdilution protocol M27-A3 for the echinocandin susceptibility testing of Candida spp.

Authors:  L A Vale-Silva; P Pinto; V Lopes; H Ramos; E Pinto
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-09-10       Impact factor: 3.267

Review 3.  Recent trends in molecular diagnostics of yeast infections: from PCR to NGS.

Authors:  Toni Gabaldón
Journal:  FEMS Microbiol Rev       Date:  2019-09-01       Impact factor: 16.408

4.  Susceptibility tests of oropharyngeal Candida albicans from egyptian patients to fluconazole determined by three methods.

Authors:  Noha El-Mashad; Mona F Foad; Niveen Saudy; Dalia A Salem
Journal:  Braz J Microbiol       Date:  2012-06-01       Impact factor: 2.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.